Catalyst Wire Dossier Catalyst Wire Dossier

AndroGel 1.62%

testosterone · AbbVie
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for AndroGel 1.62%, covering 2014-10-01 to 2017-12-07. Get the full timeline:

Most recent: Clinical Trial Update: An Open-Label Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure to Testosterone Gel 1.62% Applied to the Upper Arms and Shoulders and Use of a T-shirt Barrier [Phase 1]

See pricing